Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy (NCT07186192)

🧪 Interventions in This Study

• Educational Intervention (OTHER)
• Health Telemonitoring (PROCEDURE)
• Questionnaire Administration (OTHER)
• Best Practice (OTHER)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patient Inclusion Criteria Informed Consent and Willingness to Participate
2. Documented informed consent of the participant and/or legally authorized representative Age and Language Criteria
3. Age ≥ 18 years old at the time of enrollment
4. Ability to read and understand English or Spanish for Questionnaires Nature of Illness and Treatment Related Criteria
5. Relapsed or refractory hematologic malignancy
6. Scheduled to receive outpatient standard of care (SOC) CAR-T therapy
7. Has a FCG committed to living with the patient for the duration of the study Family Caregiver Inclusion Criteria Informed Consent and Willingness to Participate
8. Documented informed consent of the participant and/or legally authorized representative Age and Language Criteria
9. Age ≥ 18 years old at the time of enrollment
10. Ability to read and understand English or Spanish for Questionnaires Nature of Illness and Treatment Related Criteria
11. Family member or friend identified by the patient and defined as a person who knows the patient well and is involved in the patient's medical care

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• City of Hope Medical Center — Duarte, California

📞 Contact the Study Coordinator

Phone: (626) 218-3122

Email: vsun@coh.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hematologic Malignancies

• A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant — Basking Ridge, New Jersey
• PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) — Duarte, California
• APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies — Jacksonville, Florida
• IVIG for Infection Prevention After CAR-T-Cell Therapy — Duarte, California
• Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies — Madison, Wisconsin

Explore by condition: All Hematologic Malignancies clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.